Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00002817

Vaccine Therapy in Treating Patients With Metastatic Melanoma

INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA

Sponsor: National Cancer Institute (NCI)

Interventions sargramostim vaccinia-GM-CSF vaccine

Updated 6 times since 2017 Last updated: Jan 9, 2014 Started: Apr 30, 1996

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Melanoma (Skin) and is currently ongoing. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1/PHASE2
Sep 2024 — Feb 2026 [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Apr 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States